文献速递真实世界研究与卫生经济流行病学与生物统计

中低收入国家重症/危重症患者COVID快速诊断检测的成本效果:一项建模研究

Cost-effectiveness of COVID rapid diagnostic tests for patients with severe/critical illness in low- and middle-income countries: A modeling study.
PubMed 文献 · PLoS Med · 2024-07-18

该建模研究评估了在中低收入国家使用COVID快速诊断检测(RDT)指导重症患者治疗的成本效果,按国家收入水平、SARS-CoV-2流行率和检测方案(不检测、RDT、PCR及组合)进行区分。研究发现,对重症COVID样疾病患者进行SARS-CoV-2检测在所有中低收入国家均可能具有成本效果,但仅在某些情况下如此;最优算法取决于国家收入水平、卫生预算、患者COVID怀疑程度和流感流行率。

要点

  • 对重症COVID样疾病患者进行SARS-CoV-2检测在所有中低收入国家均可能具有成本效果,但仅在某些情况下如此。
  • 在低收入和部分中低收入国家,仅应对COVID高度怀疑的患者使用RDT检测,其他患者应假定无COVID。
  • 在部分中低收入和中高收入国家,疑似重症COVID病例几乎均应检测,高怀疑者阴性结果应经PCR确认。

核心结论

  • COVID检测用于指导中低收入国家重症COVID样疾病患者的治疗可能具有成本效果,最优算法取决于国家收入水平、卫生预算、患者COVID怀疑程度和流感流行率。
  • 进一步研究以更好地描述皮质类固醇的非预期效应(尤其是对流感病例)可改善中低收入国家COVID样症状患者治疗决策。

研究设计与样本

  • 采用决策树模型评估中低收入国家COVID检测的成本效果,按国家收入水平、SARS-CoV-2流行率和检测场景(不检测、RDT、PCR及组合)区分结果。
  • 中低收入国家专家定义了现实护理路径和治疗选择,采用医疗服务提供者视角和净货币效益方法评估每个检测场景的预期(COVID症状缓解)和非预期(治疗副作用)健康与经济影响。
  • 分析中考虑了皮质类固醇的副作用,并纳入COVID样疾病(如流感)的流行率,因为副作用取决于治疗和患者基础疾病。

主要发现

  • 对重症COVID样疾病患者进行SARS-CoV-2检测在所有中低收入国家均可能具有成本效果,但仅在某些情况下如此。
  • 疑似COVID病例中高流感流行率可改善成本效果,因为错误给予皮质类固醇可能加重流感结局。
  • 在低收入和部分中低收入国家,仅应对COVID高度怀疑的患者使用RDT检测,其他患者应假定无COVID。
  • 在部分中低收入和中高收入国家,疑似重症COVID病例几乎均应检测;高初始怀疑患者的阴性结果应经PCR确认,流感暴发期间低初始怀疑患者的阳性结果也应经PCR确认。
  • 在较高收入中低收入国家,当有检测支持时使用白介素-6受体阻滞剂也可能具有成本效果;在低收入国家其具有成本效果的价格为每疗程162至406美元,低于当前价格。

局限性

  • 分析的主要局限性是模型中部分参数因数据有限而存在较大不确定性,最显著的是当前标准治疗下COVID死亡率的数据有限,以及皮质类固醇对重症流感患者影响的证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapid diagnostic tests (RDTs) for coronavirus disease (COVID) are used in low- and middle-income countries (LMICs) to inform treatment decisions. However, to date, it is unclear when this use is cost-effective. Existing analyses are limited to a narrow set of countries and uses. The aim of this study is to assess the cost-effectiveness of COVID RDTs to inform the treatment of patients with severe illness in LMICs, considering real world practice. METHODS AND FINDINGS: We assessed the cost-effectiveness of COVID testing across LMICs using a decision tree model, differentiating results by country income level, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) prevalence, and testing scenario (none, RDTs, polymerase chain reaction tests-PCRs and combinations). LMIC experts defined realistic care pathways and treatment options. Using a healthcare provider perspective and net monetary benefit approach, we assessed both intended (COVID symptom alleviation) and unintended (treatment side effects) health and economic impacts for each testing scenario. We included the side effects of corticosteroids, which are often the only available treatment for COVID. Because side effects depend both on the treatment and the patient's underlying illness (COVID or COVID-like illnesses, such as influenza), we considered the prevalence of COVID-like illnesses in our analyses. We found that SARS-CoV-2 testing of patients with severe COVID-like illness can be cost-effective in all LMICs, though only in some circumstances. High influenza prevalence among suspected COVID cases improves cost-effectiveness, since incorrectly provided corticosteroids may worsen influenza outcomes. In low- and some lower-middle-income countries, only patients with a high index of suspicion for COVID should be tested with RDTs, while other patients should be presumed to not have COVID. In some lower-middle-income and upper-middle-income countries, suspected severe COVID cases should almost always be tested. Further, in these settings, negative test results in patients with a high initial index of suspicion should be confirmed through PCR and, during influenza outbreaks, positive results in patients with a low initial index of suspicion should also be confirmed with a PCR. The use of interleukin-6 receptor blockers, when supported by testing, may also be cost-effective in higher-income LMICs. The cost at which they would be cost-effective in low-income countries ($162 to $406 per treatment course) is below current prices. The primary limitation of our analysis is substantial uncertainty around some of the parameters in our model due to limited data, most notably on current COVID mortality with standard of care, and insufficient evidence on the impact of corticosteroids on patients with severe influenza. CONCLUSIONS: COVID testing can be cost-effective to inform treatment of LMIC patients with severe COVID-like disease. The optimal algorithm is driven by country income level and health budgets, the level of suspicion that the patient may have COVID, and influenza prevalence. Further research to better characterize the unintended effects of corticosteroids, particularly on influenza cases, could improve decision making around the treatment of those with COVID-like symptoms in LMICs.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Bonnet G, Bimba J, Chavula C, et al. Cost-effectiveness of COVID rapid diagnostic tests for patients with severe/critical illness in low- and middle-income countries: A modeling study. PLoS Med. 2024. PMID: 39024370. doi:10.1371/journal.pmed.1004429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。